BRIEF-Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter Results

Reuters01-09

Jan 9 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:

RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY, UNAUDITED FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUES AND UPCOMING MILESTONES
RHYTHM PHARMACEUTICALS INC - MARCH 20, 2026 PDUFA GOAL DATE FOR SNDA FOR SETMELANOTIDE IN ACQUIRED HYPOTHALAMIC OBESITY
RHYTHM PHARMACEUTICALS INC - TOPLINE DATA FROM PHASE 3 EMANATE TRIAL EXPECTED Q1 2026
RHYTHM PHARMACEUTICALS INC - FY 2025 PRELIM PRODUCT REVENUES ABOUT $194 MILLION, UP 50% FROM FY2024
RHYTHM PHARMACEUTICALS INC - PRELIM Q4 2025 IMCIVREE REVENUES ABOUT $57 MILLION, UP 11% FROM Q3

Source text: ID:nGNX5s2TCj

Further company coverage: RYTM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602379917?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602379917","market":"fut","top_or_hot":-1,"title":"BRIEF-Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter Results","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter Results</title></head><body><p><span>Jan 9 (Reuters)</span><span> - </span>Rhythm Pharmaceuticals Inc <span>RYTM.O</span>:</p><ul><li><p>RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY, UNAUDITED FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUES AND UPCOMING MILESTONES</p></li><li><p>RHYTHM PHARMACEUTICALS INC - MARCH 20, 2026 PDUFA GOAL DATE FOR SNDA FOR SETMELANOTIDE IN ACQUIRED HYPOTHALAMIC OBESITY</p></li><li><p>RHYTHM PHARMACEUTICALS INC - TOPLINE DATA FROM PHASE 3 EMANATE TRIAL EXPECTED Q1 2026</p></li><li><p>RHYTHM PHARMACEUTICALS INC - FY 2025 PRELIM PRODUCT REVENUES ABOUT $194 MILLION, UP 50% FROM FY2024</p></li><li><p>RHYTHM PHARMACEUTICALS INC - PRELIM Q4 2025 IMCIVREE REVENUES ABOUT $57 MILLION, UP 11% FROM Q3</p></li></ul><p>Source text: <span>ID:nGNX5s2TCj</span></p><p>Further company coverage: <span>RYTM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-09 21:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter Results</title></head><body><p><span>Jan 9 (Reuters)</span><span> - </span>Rhythm Pharmaceuticals Inc <span>RYTM.O</span>:</p><ul><li><p>RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY, UNAUDITED FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUES AND UPCOMING MILESTONES</p></li><li><p>RHYTHM PHARMACEUTICALS INC - MARCH 20, 2026 PDUFA GOAL DATE FOR SNDA FOR SETMELANOTIDE IN ACQUIRED HYPOTHALAMIC OBESITY</p></li><li><p>RHYTHM PHARMACEUTICALS INC - TOPLINE DATA FROM PHASE 3 EMANATE TRIAL EXPECTED Q1 2026</p></li><li><p>RHYTHM PHARMACEUTICALS INC - FY 2025 PRELIM PRODUCT REVENUES ABOUT $194 MILLION, UP 50% FROM FY2024</p></li><li><p>RHYTHM PHARMACEUTICALS INC - PRELIM Q4 2025 IMCIVREE REVENUES ABOUT $57 MILLION, UP 11% FROM Q3</p></li></ul><p>Source text: <span>ID:nGNX5s2TCj</span></p><p>Further company coverage: <span>RYTM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA4W9Q0P:1","article_id":"2602379917","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602379917","pubTimestamp":1767965954,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter ResultsJan 9 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY, UNAUDITED FOURTH Q","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4585":"ETF&股票定投概念","RYTM":"Rhythm Pharmaceuticals Inc.","BK4588":"碎股"},"translate_title":"BRIEF-Rhythm Pharmaceuticals公布未经审计的第四季度初步业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYTM":0.9},"content_text":"BRIEF-Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter ResultsJan 9 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY, UNAUDITED FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUES AND UPCOMING MILESTONESRHYTHM PHARMACEUTICALS INC - MARCH 20, 2026 PDUFA GOAL DATE FOR SNDA FOR SETMELANOTIDE IN ACQUIRED HYPOTHALAMIC OBESITYRHYTHM PHARMACEUTICALS INC - TOPLINE DATA FROM PHASE 3 EMANATE TRIAL EXPECTED Q1 2026RHYTHM PHARMACEUTICALS INC - FY 2025 PRELIM PRODUCT REVENUES ABOUT $194 MILLION, UP 50% FROM FY2024RHYTHM PHARMACEUTICALS INC - PRELIM Q4 2025 IMCIVREE REVENUES ABOUT $57 MILLION, UP 11% FROM Q3Source text: ID:nGNX5s2TCjFurther company coverage: RYTM.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602379917","isCrawlerRequest":true}